CR9520A - INHIBITORS OF PHOSPHOLIPASE A2 CITOSOLICA - Google Patents

INHIBITORS OF PHOSPHOLIPASE A2 CITOSOLICA

Info

Publication number
CR9520A
CR9520A CR9520A CR9520A CR9520A CR 9520 A CR9520 A CR 9520A CR 9520 A CR9520 A CR 9520A CR 9520 A CR9520 A CR 9520A CR 9520 A CR9520 A CR 9520A
Authority
CR
Costa Rica
Prior art keywords
phospholipase
inhibitors
citosolica
enzymes
cytosolic
Prior art date
Application number
CR9520A
Other languages
Spanish (es)
Inventor
C Mckew John
L Lee Katherine
Chen Lilhren
Vargas Richard
D Clark James
Williams Cara
Clerin Valerie
Marusic Suzana
Pong Kevin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9520A publication Critical patent/CR9520A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion provee inhibidores quimicos de la actividad de diversas enzimas fosfolipasa, particularmente de las enzimas fosfolipasa A2 citosolica (cpla2), mas particularmente incluyendo inhibidores de las enzimas fosfolipasa A2 alfa citosolica (cpla2a)The invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cpla2), more particularly including phospholipase A2 alpha cytosolic enzymes inhibitors (cpla2a)

CR9520A 2005-05-27 2007-11-14 INHIBITORS OF PHOSPHOLIPASE A2 CITOSOLICA CR9520A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68556405P 2005-05-27 2005-05-27

Publications (1)

Publication Number Publication Date
CR9520A true CR9520A (en) 2008-02-20

Family

ID=37188759

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9520A CR9520A (en) 2005-05-27 2007-11-14 INHIBITORS OF PHOSPHOLIPASE A2 CITOSOLICA

Country Status (32)

Country Link
US (3) US7557135B2 (en)
EP (2) EP2248801A1 (en)
JP (1) JP5116666B2 (en)
KR (1) KR101353982B1 (en)
CN (2) CN101184729B (en)
AR (1) AR054195A1 (en)
AT (1) ATE489364T1 (en)
AU (1) AU2006251946B2 (en)
BR (1) BRPI0610049A2 (en)
CA (1) CA2607857C (en)
CR (1) CR9520A (en)
CY (1) CY1111151T1 (en)
DE (1) DE602006018451D1 (en)
DK (1) DK1891006T3 (en)
ES (1) ES2354908T3 (en)
GT (1) GT200600228A (en)
HN (1) HN2006019513A (en)
IL (1) IL186912A (en)
MX (1) MX2007014589A (en)
MY (1) MY144672A (en)
NI (1) NI200700287A (en)
NO (1) NO20075627L (en)
NZ (1) NZ563736A (en)
PE (1) PE20061426A1 (en)
PL (1) PL1891006T3 (en)
PT (1) PT1891006E (en)
RU (1) RU2433997C2 (en)
SI (1) SI1891006T1 (en)
SV (1) SV2008002551A (en)
TW (1) TW200718687A (en)
UA (1) UA91053C2 (en)
WO (1) WO2006128142A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
HN2004000536A (en) * 2003-12-16 2009-02-18 Wyeth Corp A SYNTHESIS PROCEDURE FOR THE REDUCTIVE RENTAL OF THE POSITION C-3 OF INDOLES
IL161579A0 (en) 2004-04-22 2004-09-27 Mor Research Applic Ltd ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF
US8029815B2 (en) 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
WO2007140317A2 (en) * 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
IL178401A (en) * 2006-09-28 2012-04-30 Univ Ben Gurion USE OF ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2 IN THE TREATMENT OF CANCER
CL2007003143A1 (en) * 2006-10-31 2008-01-25 Wyeth Corp Pharmaceutical composition comprising a compound derived from indole and a carrier system comprising 10-50% of a first solubilizer, 5-50% of a second solubilizer, 10-30% of a first diluent and 1-15% of a second diluent ; prepration process; and dosage form.
BRPI0718042A2 (en) * 2006-10-31 2013-11-12 Wyeth Corp SEMISOLID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS
US8293781B2 (en) 2007-03-29 2012-10-23 Daiichi Sankyo Company, Limited Indole derivatives having cPLA2 inhibiting activity and applications and production methods of the same
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US9011821B2 (en) 2010-06-18 2015-04-21 Whitehead Institute For Biomedical Research PLA2G16 as a target for antiviral compounds
EP2614144B1 (en) 2010-09-08 2015-07-22 Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection
GB201401904D0 (en) 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
WO2015129592A1 (en) * 2014-02-28 2015-09-03 住友化学株式会社 Method for producing 2-(halogenomethyl)-3-methylnitrobenzene
CN103804150A (en) * 2014-03-01 2014-05-21 江苏斯威森生物医药工程研究中心有限公司 Preparation method of 3,4-dimethoxybenzyl bromide
CN108017522B (en) * 2017-11-16 2021-01-05 贵州大学 Preparation process of 2, 6-dibromobenzene methane sulfonyl chloride
WO2020236777A1 (en) * 2019-05-20 2020-11-26 Saint Louis University Reprogramming of lipid metabolism to inhibit t cell senescence and enhance tumor immunotherapy
TWI770527B (en) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot modulators and methods of use thereof
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (en) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Process for preparing COT inhibitor compounds
US20230338529A1 (en) * 2020-08-06 2023-10-26 The Children's Medical Center Corporation Compositions for altering a microglial cell, and methods of use therefore

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH48411A (en) 1909-07-19 1910-10-17 Stephen Alley Tools for fitting and removing elastic tires from vehicle wheels
GB1148908A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Indole derivatives and processes for making them
FR1492929A (en) 1966-05-11 1967-08-25 Roussel Uclaf Novel substituted 1- (omega-carboxyalkyl) indoles and method of preparation
US3505354A (en) * 1967-05-18 1970-04-07 Geigy Chem Corp 2-methyl-3-p-halobenzoylindole-n-aliphatic acids
DE1816335A1 (en) 1968-12-21 1970-07-09 Thiemann Gmbh Chem Pharm Fabri 2-methyl-5-alkoxy-3-acyl-indole-1-acetic - acid and esters thereof
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4271263A (en) * 1980-05-15 1981-06-02 Minnesota Mining And Manufacturing Company Thermally developable photosensitive compositions containing acutance agents
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4654360A (en) * 1984-06-01 1987-03-31 Syntex (U.S.A.) Inc. 1,2,3-trisubstituted indoles for treatment of inflammation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
ES2045420T3 (en) 1988-04-13 1994-01-16 Ici America Inc CYCLIC AMIDES.
GB8906032D0 (en) 1988-04-14 1989-04-26 Ici America Inc Hetera-aliphatic carboxamides
US5166170A (en) * 1989-07-03 1992-11-24 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (en) 1989-10-27 1991-09-13 American Home Prod PROCESS FOR THE PREPARATION OF INDOLE-, INDENO-, PYRANOINDOLE- AND TETRA-HYDROCARBAZOLE-ALCANOIC ACID DERIVATIVES, OR WHICH ARE USEFUL AS PLA2 INHIBITORS AND LIPOXIGENASE
US5229516A (en) * 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
US5622832A (en) 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5190968A (en) * 1991-09-30 1993-03-02 Merck Frosst Canada, Inc. (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5206377A (en) * 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
IL104869A (en) 1992-05-13 1997-11-20 Syntex Inc SUBSTITUTED INDOLE, AZAINDOLE AND TETRAHYDRO-1H-PYRROLO- £2,3-c| PYRIDIN-7-ONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5288743A (en) * 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
DE4338770A1 (en) 1993-11-12 1995-05-18 Matthias Dr Lehr Indole-2-alkanoic acids and their derivatives as inhibitors of phospholipase A¶2¶
US5686481A (en) * 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
ATE255090T1 (en) 1996-08-01 2003-12-15 Merckle Gmbh ACYLPYRROLDICARBONONIC ACIDS AND ACYLINDOLICARBONONIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2
JP2000516958A (en) 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド Phospholipase enzyme inhibitors
US6630496B1 (en) * 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
EA200000868A1 (en) * 1998-02-25 2001-04-23 Дженетикс Инститьют, Инк. PHOSPHOLIPAZ INHIBITORS
SK12752000A3 (en) 1998-02-25 2001-03-12 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
HUP0100156A3 (en) 1998-02-25 2002-12-28 Genetics Inst Inc Cambridge Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6424105B1 (en) 1999-06-08 2002-07-23 Camco International, Inc. Real-time control of feedback signals to a motor for optimum performance
WO2002057323A1 (en) * 2001-01-22 2002-07-25 Sony Corporation Solvent absorbing resin and method for preparation thereof
US6635771B2 (en) * 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
DK1451154T3 (en) * 2001-12-03 2008-05-19 Wyeth Corp Inhibitors of cytosolic phospholipase A2
US7101875B2 (en) * 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US6984735B2 (en) * 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US7605156B2 (en) * 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
CA2511925C (en) 2002-12-31 2012-11-13 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of phosphatases, compositions and uses thereof
US7439249B2 (en) * 2002-12-31 2008-10-21 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
TW200510305A (en) 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7582771B2 (en) * 2003-09-03 2009-09-01 Wyeth Process for the synthesis of cPLA2 inhibitors
US20050053600A1 (en) * 2003-09-09 2005-03-10 Lane Thomas E. Methods for treating rheumatoid arthritis
US7342119B2 (en) * 2003-09-30 2008-03-11 Wyeth Holdings Corporation Process for the synthesis of a CPLA2 inhibitor
HN2004000536A (en) * 2003-12-16 2009-02-18 Wyeth Corp A SYNTHESIS PROCEDURE FOR THE REDUCTIVE RENTAL OF THE POSITION C-3 OF INDOLES
AR053410A1 (en) * 2004-08-19 2007-05-09 Wyeth Corp PROCESS FOR SYNTHESIS OF INDOLES N-RENTED C-2, C-3 SUBSTITUTED. INTERMEDIARY COMPOUNDS
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
WO2007140317A2 (en) * 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis

Also Published As

Publication number Publication date
US20100029645A1 (en) 2010-02-04
US20100022536A1 (en) 2010-01-28
PE20061426A1 (en) 2007-01-24
IL186912A (en) 2012-05-31
WO2006128142A8 (en) 2007-12-27
CN102040550A (en) 2011-05-04
AU2006251946A1 (en) 2006-11-30
DE602006018451D1 (en) 2011-01-05
MX2007014589A (en) 2008-01-21
JP5116666B2 (en) 2013-01-09
HK1152710A1 (en) 2012-03-09
AR054195A1 (en) 2007-06-06
MY144672A (en) 2011-10-31
CY1111151T1 (en) 2015-06-11
HN2006019513A (en) 2011-03-02
EP1891006B1 (en) 2010-11-24
ES2354908T3 (en) 2011-03-21
EP1891006A2 (en) 2008-02-27
UA91053C2 (en) 2010-06-25
CN101184729B (en) 2011-02-16
PT1891006E (en) 2011-01-26
RU2433997C2 (en) 2011-11-20
GT200600228A (en) 2006-12-26
KR101353982B1 (en) 2014-02-18
WO2006128142A3 (en) 2007-03-29
US7557135B2 (en) 2009-07-07
NZ563736A (en) 2010-11-26
DK1891006T3 (en) 2011-01-24
KR20080021618A (en) 2008-03-07
EP2248801A1 (en) 2010-11-10
BRPI0610049A2 (en) 2010-05-25
CN102040550B (en) 2012-10-03
NO20075627L (en) 2008-01-03
CA2607857C (en) 2014-02-11
WO2006128142A2 (en) 2006-11-30
CA2607857A1 (en) 2006-11-30
PL1891006T3 (en) 2011-05-31
IL186912A0 (en) 2008-02-09
CN101184729A (en) 2008-05-21
ATE489364T1 (en) 2010-12-15
NI200700287A (en) 2008-05-27
AU2006251946B2 (en) 2011-05-12
US20070004719A1 (en) 2007-01-04
JP2008542303A (en) 2008-11-27
TW200718687A (en) 2007-05-16
SI1891006T1 (en) 2011-02-28
RU2007140910A (en) 2009-07-10
US8283373B2 (en) 2012-10-09
HK1113680A1 (en) 2008-10-10
SV2008002551A (en) 2008-07-23

Similar Documents

Publication Publication Date Title
CR9520A (en) INHIBITORS OF PHOSPHOLIPASE A2 CITOSOLICA
EP1931250A4 (en) BEAM OF ELECTRODES
HN2003000227A (en) KINASE INHIBITORS
EA200701918A1 (en) PROTEIN LIPOKALIN
NO20071309L (en) Method of expansion
CY1109911T1 (en) PYRROLOVENZODIAZEPINES
UY29612A1 (en) CHEMICAL COMPOUNDS II
EP1963530A4 (en) ACTIVE POLYMERAS COUPLED ON SURFACES
EP1494614A4 (en) BREAKING BY ENZYMES OF BIOTERIAL BIOFILMS
DK1848718T3 (en) E1 activation enzyme inhibitors
NO20044597L (en) Chemical connections
CR9223A (en) 18-METIL-19-NOR-17-PREGN-4-EN-21, 17-CARBOLACTONES, AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM
PA8618901A1 (en) BIARIL SULFONAMIDS AND METHOD FOR THE USE OF THE SAME
CR8312A (en) NEW SULFONAMIDS AS PHYTOSANITARY AGENTS
EP1941060A4 (en) JMJC DOMAIN PROTEIN METHYLASE
EP1817276A4 (en) INHIBITORS OF CYSTEINE PROTEASE CATHEPSINE
PA8667201A1 (en) NEW PHARMACEUTICAL COMPOUNDS
DK2179035T3 (en) MODIFIED BACTERIOPHAGIC INCLUDING AN ALFA / BETA-SASP (SMALL ACID-SOLUBLE SPORE PROTEIN) GENE
SV2006002001A (en) QUINASE INHIBITORS REF. X - 16437
DE602005018653D1 (en) ACTIVE SELECTION OF THE CONFIRMATION SOURCE
EA200801145A1 (en) SPYROCYCLIC DERIVATIVES OF HINAZOLIN AS PDE7 INHIBITORS
CR8813A (en) NEW ASSOCIATION OF AN INHIBITOR OF THE SINUSUAL CURRENT L1 AND OF A CALCIUM INHIBITOR AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EP1704861A4 (en) INHIBITOR OF LIPASE
PA8795401A1 (en) ASSOCIATION BETWEEN AN ANTIATEROTROMBOTIC AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME
PA8645401A1 (en) PROCEDURE FOR THE MANUFACTURE OF IMIDAZOLIC COMPOUNDS, THEIR SALTS AND THEIR PSEUDOPOLIMORPHES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)